Billionaires Fast‑Track Experimental Medicine

Wealthy individuals are directly enabling and accelerating experimental clinical interventions — securing emergency authorizations, arranging specialized care, and founding large private institutes — which can shift what gets studied and who gets access. This dynamic can produce rapid innovation but also raises questions about equity, regulatory standards, and the social direction of biomedical research. — If private capital increasingly determines which medical experiments proceed, policy must address access, oversight, conflicts of interest, and the democratic allocation of research priorities.